Chinese CRO ShangPharma Moves Into Biologics To Follow Customer Trend
This article was originally published in PharmAsia News
Executive Summary
BEIJING - The leadership of Chinese contract research organization ShangPharma this week outlined plans to continue expanding the outfit's drug and biopharmaceutical research services through next year to attract more of the top international players
You may also be interested in...
China's Leading CROs Go On Shopping Spree To Become One-Stop Vendors
China's leading contract research organizations, Wuxi PharmaTech and ShangPharma, in a race to win over Big Pharma with integrated service platforms, announced separate deals Oct. 24 to expand into new strategic areas
China's Leading CROs Go On Shopping Spree To Become One-Stop Vendors
China's leading contract research organizations, Wuxi PharmaTech and ShangPharma, in a race to win over Big Pharma with integrated service platforms, announced separate deals Oct. 24 to expand into new strategic areas
Chinese CRO ShangPharma Moving Into Biologics, Small-scale Manufacturing To Broaden Customer Pool
BEIJING - Limited-scale pharmaceutical manufacturing for research and biologics testing services are likely to become primary engines of expansion in the future for Chinese contract research organization ShangPharma, according to the Shanghai-based outfit's leadership